Novo Nordisk Raises 2026 Sales and Profit Outlook on Strong GLP-1 Sales

SentiSense · Published · Updated

Novo Nordisk reports adjusted operating profit of DKK 33,389 million for Q2 2026 and raises full-year outlook. The company's strong sales of GLP-1 tre...

Sign in to read the full story. Free accounts include 20 full reads a month.

Sign in or create a free account

Powered by SentiSense - Intelligent Market Analysis